Diabetes, Atherosclerosis, and Stenosis by AI

Abstract

OBJECTIVE This study evaluates the relationship between atherosclerotic plaque characteristics (APCs) and angiographic stenosis severity in patients with and without diabetes. Whether APCs differ based on lesion severity and diabetes status is unknown. RESEARCH DESIGN AND METHODS We retrospectively evaluated 303 subjects from the Computed TomogRaphic Evaluation of Atherosclerotic Determinants of Myocardial IsChEmia (CREDENCE) trial referred for invasive coronary angiography with coronary computed tomographic angiography (CCTA) and classified lesions as obstructive (≥50% stenosed) or nonobstructive using blinded core laboratory analysis of quantitative coronary angiography. CCTA quantified APCs, including plaque volume (PV), calcified plaque (CP), noncalcified plaque (NCP), low-density NCP (LD-NCP), lesion length, positive remodeling (PR), high-risk plaque (HRP), and percentage of atheroma volume (PAV; PV normalized for vessel volume). The relationship between APCs, stenosis severity, and diabetes status was assessed. RESULTS Among the 303 patients, 95 (31.4%) had diabetes. There were 117 lesions in the cohort with diabetes, 58.1% of which were obstructive. Patients with diabetes had greater plaque burden (P = 0.004). Patients with diabetes and nonobstructive disease had greater PV (P = 0.02), PAV (P = 0.02), NCP (P = 0.03), PAV NCP (P = 0.02), diseased vessels (P = 0.03), and maximum stenosis (P = 0.02) than patients without diabetes with nonobstructive disease. APCs were similar between patients with diabetes with nonobstructive disease and patients without diabetes with obstructive disease. Diabetes status did not affect HRP or PR. Patients with diabetes had similar APCs in obstructive and nonobstructive lesions. CONCLUSIONS Patients with diabetes and nonobstructive stenosis had an association to similar APCs as patients without diabetes who had obstructive stenosis. Among patients with nonobstructive disease, patients with diabetes had more total PV and NCP.

Eradicating Atherosclerotic Events by Targeting Early Subclinical Disease: It Is Time to Retire the Therapeutic Paradigm of Too Much, Too Late

“…103,108 Use CTA, which is currently the best, least-invasive method to accurately visualize the arterial wall, 137 to identify individuals in this age range who have image-evident subclinical atherosclerotic plaques in their coronary arteries. CTA has additional advantages: low radiation dose, inexpensive, visualizes noncalcified (soft) and calcified (hard) plaques, gives information about additional pertinent plaque characteristics [137][138][139] ; the readings are becoming more automated 137,[140][141][142] hence less expensive and more reliable; the contrast agents are safer and given in lower doses; and the test can be used to follow In South Korea, usually radical thyroidectomy followed by lifelong thyroid hormone replacement; about one-third underwent partial thyroidectomy 126 If backed by clinical-trial data, brief induction-phase therapy of intensive plasma apoB lowering and then maintenance-phase therapy (proposed in reference 78 and updated here)…”

The Multifaceted Actions of Polyphenols in the Management of Type-2 Diabetes Mellitus

“…Finally, several reports have demonstrated that polyphenols can actively reduce the undesired consequences of the activation of RAGE, either by interfering with receptor signaling as well as by reducing its expression [147][148][149] 8. Lipid metabolism T2DM has been widely associated with an increased risk for atherosclerotic cardiovascular disease which is closely related to raised plasmatic LDL levels with important oxidative changes, [150] which support diabetic hyperlipidemia and accelerated atherosclerosis, increasing the risk of macrovascular complication and cardiovascular morbidity. Noteworthy, LDL is a highly sensitive molecule to hyperglycemia-induced hyperglycemia damage and modification, making them highly pathogenic and atherogenic [151,152].…”

Discovering hidden patterns: Association rules for cardiovascular diseases in type 2 diabetes mellitus

“…This program[ 8 , 9 ] provides an overview of disease predictions based on computational intelligence. Available data suggest that neural networks were used for lumen wall evaluation, vessel contour determination, and plaque characterization, optimizing for phase with each vessel segment analysis[ 11 ].…”